Bio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the stock.

Bio-Path Stock Performance

Shares of Bio-Path stock opened at $0.84 on Wednesday. The business has a 50 day moving average of $0.89 and a 200 day moving average of $1.08. Bio-Path has a 52 week low of $0.59 and a 52 week high of $9.99.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.